Oman vs Sur: HIV-positive TB patients on ART (antiretroviral therapy)
Oman
100.0%
in 2024
Sur
82.0%
in 2024
Oman rank
1st
Sur rank
2nd
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Oman
- Sur
How they compare
Oman currently reports 100.0% against 82.0% in Sur, a difference of 18.0%.
That makes Oman's figure about 1.2 times Sur's.
The two have swapped places 4 times across 19 shared years of data; in 2003 it was Oman ahead.
Oman ranks 1st and Sur ranks 2nd of 144 countries.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Oman | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 27.5% | 72.5% | Oman |
| 2010s | 93.1% | 66.3% | 26.8% | Oman |
| 2020s | 91.4% | 75.8% | 15.6% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Oman or Sur?
- Oman, at 100.0% against 82.0% in Sur as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Oman and Sur?
- 18.0%, with Oman ahead.
- How many years of comparable data are there for Oman and Sur?
- 19 years are reported by both, from 2003 to 2024.
- How do Oman and Sur rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Oman ranks 1st and Sur ranks 2nd of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.